Evidera’s thought leaders have guided preparation for, and interactions with, the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute for Health and Care Excellence (NICE) and the German Federal Joint Committee (GBA). Our experts have influenced decision making through work with NICE, the Institute for Quality and Efficiency in Healthcare (IQWiG), the FDA, the Centers for Medicare & Medicaid Services (CMS) and France’s Haute Autorité de Santé (HAS).
We draw from the insight and experience of experts across Evidera as well as our network of external collaborators. This breadth of knowledge and depth of experience provides valuable strategic intelligence to help identify a product’s value proposition and determine the best approaches for generating the right evidence to support that value proposition. Our strategic guidance will help you improve the positioning of your product and its market access potential.
Identify the optimal strategy for generating the appropriate evidence to support your product’s value proposition and deliver it to target decision makers at the right time.
Ensure the components of your multifaceted evidence generation plan are strategically integrated and coordinated to deliver the highest quality evidence in a cost-efficient and timely manner.